FDA clears GTX-102 trial to resume in the US

FAST are very excited to be able to share this press release which was issued by GeneTx and Ultragenyx today, 27th September announcing that the FDA have removed the clinical hold on Phase 1/2 Clinical Study of GTX-102 for the treatment of Angelman Syndrome in the US.

Read the full press release here.